{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:56:16Z","timestamp":1776473776171,"version":"3.51.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-4T32EB005970"],"award-info":[{"award-number":["T32-4T32EB005970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA023100"],"award-info":[{"award-number":["P30 CA023100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jtct.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T20:58:06Z","timestamp":1634245086000},"page":"30.e1-30.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas"],"prefix":"10.1016","volume":"28","author":[{"given":"Aaron M.","family":"Goodman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Holden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-1554","authenticated-orcid":false,"given":"Ah-Reum","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1771-7230","authenticated-orcid":false,"given":"Lisa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-255X","authenticated-orcid":false,"given":"Kerry D.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyad","family":"Almasri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"McLennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin H.","family":"Jahromi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7026-2506","authenticated-orcid":false,"given":"Carl","family":"Hoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Mulroney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-4428","authenticated-orcid":false,"given":"Dimitrios","family":"Tzachanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward D.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor J.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.jtct.2021.10.007_bib0001","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2021.10.007_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2021.10.007_bib0003","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.jtct.2021.10.007_bib0004","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1016\/j.jtct.2021.10.007_bib0005","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2021.10.007_bib0006","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2021.10.007_bib0007","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2021.10.007_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jtct.2021.10.007_bib0009","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/1078-0432.CCR-17-0454","article-title":"Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine","volume":"23","author":"Husain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jtct.2021.10.007_bib0010","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","article-title":"Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival","volume":"25","author":"Baumgartner","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2021.10.007_bib0011","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1245\/s10434-020-08331-x","article-title":"Prognostic utility of pre- and postoperative circulating tumor DNA liquid biopsies in patients with peritoneal metastases","volume":"27","author":"Baumgartner","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.jtct.2021.10.007_bib0012","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jama.2017.12131","article-title":"Cancer DNA in the circulation: the liquid biopsy","volume":"318","author":"Husain","year":"2017","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.jtct.2021.10.007_bib0013","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1158\/1078-0432.CCR-17-0291","article-title":"Development and validation of an ultradeep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer","volume":"23","author":"Janku","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jtct.2021.10.007_bib0014","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1535-7163.MCT-18-0535","article-title":"Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients","volume":"18","author":"Jensen","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.jtct.2021.10.007_bib0015","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2021.10.007_bib0016","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1158\/1535-7163.MCT-17-0360","article-title":"The mutational landscape of gastrointestinal malignancies as reflected by circulating tumor DNA","volume":"17","author":"Riviere","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.jtct.2021.10.007_bib0017","doi-asserted-by":"crossref","first-page":"9707","DOI":"10.18632\/oncotarget.7110","article-title":"Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay","volume":"7","author":"Schwaederle","year":"2016","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.jtct.2021.10.007_bib0018","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-16-2497","article-title":"Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma","volume":"23","author":"Schwaederl\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"346","key":"10.1016\/j.jtct.2021.10.007_bib0019","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"issue":"17","key":"10.1016\/j.jtct.2021.10.007_bib0020","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/1078-0432.CCR-17-0231","article-title":"Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy","volume":"23","author":"Weiss","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.jtct.2021.10.007_bib0021","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2021.10.007_bib0022","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/gim.2017.56","article-title":"Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases","volume":"19","author":"Ehrich","year":"2017","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.jtct.2021.10.007_bib0023","doi-asserted-by":"crossref","first-page":"e57381","DOI":"10.1371\/journal.pone.0057381","article-title":"High-throughput massively parallel sequencing for fetal aneuploidy detection from maternal plasma","volume":"8","author":"Jensen","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jtct.2021.10.007_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109173","article-title":"Non-invasive prenatal chromosomal aneuploidy testing\u2014clinical experience: 100,000 clinical samples","volume":"9","author":"McCullough","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jtct.2021.10.007_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jama.2015.7120","article-title":"Noninvasive prenatal testing and incidental detection of occult maternal malignancies","volume":"314","author":"Bianchi","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jtct.2021.10.007_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1373\/clinchem.2017.277517","article-title":"Incidental detection of maternal neoplasia in noninvasive prenatal testing","volume":"64","author":"Dharajiya","year":"2018","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.jtct.2021.10.007_bib0027","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1373\/clinchem.2016.260034","article-title":"Using targeted sequencing of paralogous sequences for noninvasive detection of selected fetal aneuploidies","volume":"62","author":"Ellison","year":"2016","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.jtct.2021.10.007_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2016.02.030","article-title":"Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants","volume":"215","author":"Lefkowitz","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jtct.2021.10.007_bib0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pd.4712","article-title":"Application of risk score analysis to low-coverage whole genome sequencing data for the noninvasive detection of trisomy 21, trisomy 18, and trisomy 13","volume":"36","author":"Tynan","year":"2016","journal-title":"Prenat Diagn"},{"issue":"4","key":"10.1016\/j.jtct.2021.10.007_bib0030","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1373\/clinchem.2014.233312","article-title":"Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma","volume":"61","author":"Zhao","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtct.2021.10.007_bib0031","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"21","key":"10.1016\/j.jtct.2021.10.007_bib0032","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2021.10.007_bib0033","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2021.10.007_bib0034","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/10428194.2018.1474463","article-title":"Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy","volume":"60","author":"Hossain","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"10.1016\/j.jtct.2021.10.007_bib0035","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jtct.2021.10.007_bib0036","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721012987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721012987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:51Z","timestamp":1763002851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721012987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2666636721012987"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.10.007","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}